For the stated reasons above, U.S. pharmaceutical company Patient Assistance Programs (PAPs) should be an integral part of the new, reformed health care system currently being debated in Congress. U.S. pharmaceutical companies have offered these programs for years, so there should be no debate as to their assistance to low income uninsured Americans. By integrating and expanding PAPs in the current health care environment the overall cost to taxpayers will be reduced.
PAPs are highly relevant in the current health care debate. By expanding their use and coverage, they will enable other reforms to be made. U.S. pharmaceutical companies absorb the costs of these programs, so there is no taxpayer money involved.
Article comments
1 - FCEtier
Geoff,
Is your company still in business? I couldn't discern from your article how you make money if your clients are indigent. It's hard to imagine the drug companies paying someone to help them give away their meds. I've referred patients to the manufacturers countless times over the thirty years of my practice and it's surprising that you and I haven't crossed trails...